Aziz Sheikh on Muck Rack

Aziz Sheikh

United Kingdom
As seen in: PLOS, Primary Care Respiratory Medicine, Color Research & Application, Nature, Wiley, Wiley Online Library, Memory Studies, PLOS Medicine, Archives of Disease in Childhood, BMJ Open, BMJ Quality & Safety, MDPI and
Professor @EdinburghUni
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Aziz

Contact Aziz, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Reflections on 10 years of research capacity building

|
By Gwyneth Davies, Hilary Pinnock, Kathryn Ferris, Aziz Sheikh
| Nature
There are major concerns about the decline in translational research capacity in the UK with potential knock-on implications for advances in clinical care and the growth of the life sciences sector.
Open in Who Shared Issue with article?

Patient perspectives of asthma treatment and belief barriers to implementing new guidelines: a qualitative analysis of an online forum

|
By Zoe Moon, Hannah Truscott, Anna De Simoni, Louise Fleming, Mark Levy , Aziz Sheikh, Robert Horne, Grainne d’ Ancona
| Nature
Abstract For the last 40 years, the first line of asthma treatment has been short-acting beta2 agonists (SABA) used as symptom relief alongside daily inhaled corticosteroids (ICS) as preventers. New guidelines recommend replacing SABA relievers with ICS-based relievers (ICS-formoterol) because of clear risks from excess and sole use of SABA.
Open in Who Shared Issue with article?

Tocilizumab versus sarilumab among adults hospitalised with COVID-19: target trial emulation across England and Scotland

|
By Bang Zheng, Amanj Kurdi, Alain Amstutz, Amelia Green, Emily Herrett, John Tazare, Qing Wen, Viyaasan Mahalingasivam, Rebecca Smith, Brian MacKenna, Amir Mehrkar, Seb Bacon, Ben Goldacre, Chris Robertson, Aziz Sheikh, Laurie Tomlinson
| Nature
Abstract The interleukin-6 (IL-6) inhibitors tocilizumab and sarilumab have been repurposed for COVID-19 treatment. However, discrepancies exist across global and national COVID-19 guidelines, with limited data on the comparative effectiveness between these therapeutics especially during the delta/omicron periods.
Open in Who Shared Issue with article?
See all 126 licensed articles (131 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Aziz

Contact Aziz, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified